Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06681766 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
A Phase 1 study, sponsored by Larimar Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT06681766 is a Phase 1 study that was terminated before completion, run by Larimar Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT06681766, a Phase 1 study, was terminated before completion, sponsored by Larimar Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).
Interventions
- DRUG Placebo
- DRUG Nomlabofusp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2025-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06681766
The ClinicalTrials.gov registry entry for NCT06681766 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Larimar Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06681766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06681766 about?
NCT06681766 is a clinical study titled "A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia". The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).
What is the current status of trial NCT06681766?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-12-06. Estimated completion is 2025-04-27.
What interventions are being tested in trial NCT06681766?
The interventions under investigation include: Placebo (DRUG), Nomlabofusp (DRUG).
Who is sponsoring clinical trial NCT06681766?
This trial is sponsored by Larimar Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.